PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma Provides Fourth Quarter 2013 Revenue Guidance of $109 Million
PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
PDL BioPharma to Present at the 25th Annual Piper Jaffray Healthcare Conference
PDL BioPharma to Present at Upcoming Investor Conferences
PDL BioPharma Announces Third Quarter 2013 Financial Results